eNauka - pregled
Pregled prema Autor Cho, BC
Prikaz rezultata 1 do 2 od 2
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2022 | A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829) (✓) | Cho, BC; ...; Zaric, Bojan   | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC | Cho, BC; ...; Secen, Nevena M; ...; (broj, koautora 19) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |